EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B

Qiqi Ning, Jing-Hsiung James Ou iD

Viruses · 08.11.2025 · 17 (11) · 1484

DOI: 10.3390/v17111484 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 08.11.2025. Verfasst von Qiqi Ning und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. Hauptthemen laut MEDLINE: Infectious Disease Transmission, Vertical, Hepatitis B, Hepatitis B, Chronic, Hepatitis B e Antigens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis B virus (HBV) infection is a major health problem that leads to approximately one million deaths every year worldwide. Mother-to-child transmission (MTCT) is the major cause of chronic HBV infection. HBV e antigen (HBeAg) is a secretory viral protein and modulates the immunological landscape of the newborn to promote HBV persistence. HBeAg actively reprograms innate and adaptive immunity. Mechanistically, HBeAg regulates macrophage polarization, suppresses dendritic cell and natural killer (NK) cell activities, impairs T cell and B cell functions, and promotes the expansion of myeloid-derived suppressor cells (MDSCs). These multifaceted effects contribute to immune tolerance and persistent HBV infection in the offspring of carrier mothers. Clinically, HBeAg status is a critical determinant for MTCT risk stratification and intervention, particularly in resource-limited settings. Despite advances in neonatal immunoprophylaxis and maternal antiviral therapy, residual transmission of HBV persists. Emerging approaches targeting HBeAg directly or restoring antiviral immunity offer promising avenues for breaking immune tolerance and achieving HBV elimination. This review summarizes current understanding of HBeAg-mediated immune modulation and highlights strategies that are being used to disrupt MTCT and treat HBV patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Infectious Disease Transmission, VerticalHepatitis BHepatitis B, ChronicHepatitis B e AntigensPregnancy Complications, InfectiousHumansFemalePregnancy

Stichwörter der Autor:innen

HBV e antigenimmune tolerancemother-to-child transmissionpersistent HBV replication

Substanzen

Hepatitis B e Antigens

Autor:innen und Institutionen

  • Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

ORCID-Profile: Jing-Hsiung James Ou

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Ning, Q., & Ou, J. J. (2025). Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B. Viruses, 17(11), 1484. https://doi.org/10.3390/v17111484

Vancouver

Ning Q, Ou JJ. Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B. Viruses. 2025;17(11):1484. doi:10.3390/v17111484

BibTeX
@article{Ning2025,
  author = {Ning, Qiqi and Ou, Jing-Hsiung James},
  title = {Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B},
  journal = {Viruses},
  year = {2025},
  volume = {17},
  number = {11},
  pages = {1484},
  doi = {10.3390/v17111484}
}
Kostenlos starten →